TABLE 1.

Baseline characteristics (N = 22)

Characteristic	Value
Age, median (range), year	67 (37–87)
Sex, n (%)
Male	13 (54.2)
Female	11 (45.8)
Histology, n (%)
Adenocarcinoma	21 (87.5)
Squamous cell carcinoma	1 (4.2)
Others	2 (8.3)
EGFR mutation, n (%)
Exon 19 deletion	8 (33.3)
Exon 21 L858R mutation	13 (54.2)
Uncommon EGFR mutations	3 (12.5)
First prior EGFR–TKI, n (%)
Gefitinib	18 (75.0)
Erlotinib	1 (4.2)
Icotinib	3 (12.5)
Afatinib	2 (8.3)
Prior EGFR–TKI failure mode, n (%)
Dramatic progression	4 (16.7)
Gradual progression	20 (83.3)
Follow‐up period, median (range), month	9.1 (2.0–27.4)

Note: Continuous variables are given as median and the minimum/maximum range. Categorical variables are described as n (%).

Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.